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A Role for Th17 cells  
in the Immunopathogenesis  
of Atopic Dermatitis?
Antonella Di Cesare1,2, Paola Di Meglio1, and Frank O. Nestle1
Atopic dermatitis (AD) is a common inflammatory skin disease. Both epidermal 
barrier dysfunction and immunodysregulation are suggested to influence the 
pathogenesis of AD. AD has been considered a paradigmatic T helper cell (Th) 
2–mediated disease, with a switch to a Th1 cell environment during the chronic 
phase of the disease. Previously unreported findings now suggest a possible role 
for Th17 cells as well.
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Atopic dermatitis (AD) is a common, 
chronic relapsing, inflammatory skin 
disease often associated with other sys­
temic atopic disorders such as asthma, 
food allergy, and allergic rhinitis. The 
pathogenesis of AD has been attributed 
to a complex interaction among the envi­
ronment and host susceptibility genes, 
altered skin barrier function, and the 
immune system (Bieber, 2008). Typically, 
AD has been considered the paradigm 
of an allergic T helper (Th) 2–mediated 
disease, characterized by abnormal IgE 
production, peripheral eosinophilia, 
mast cell activation, and induction of 
Th2 lymphocytes expressing IL­4, IL­10, 
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and IL­13 but not IFN­γ (Wierenga et 
al., 1991). However, observations on 
the clinical evolution of the cutaneous 
lesions from an acute phase (character­
ized by erythematous papules, intense 
itching, excoriation, and serous exuda­
tion) to a chronic phase (with lichenifica­
tion) led to the development of models 
to study the progression of the disease. 
Sequential biopsies in AD patients after 
exposure to aeroallergens demonstrated 
a biphasic immunologic response char­
acterized by antigen presentation, Th2 
activation, IgE release, eosinophil recruit­
ment, and a switch toward a Th1 pheno­
type in later phases of the disease (Grewe 
et al., 1995). Eosinophils, together with 
infiltrating dendritic cells, are thought to 
be responsible for the Th2­to­Th1 switch.
Recently, the Th1/Th2 paradigm in 
autoimmunity and allergy has been revis­
ited, including a role for a new popula­
tion of IL­17–producing Th cells (Th17) 
(Weaver et al., 2007). Transforming 
growth factor (TGF)­β, IL­1β, IL­6, and 
IL­23 seem to be key factors involved in 
naive Th­cell commitment to a Th17 phe­
notype, distinguishing Th17 cells from 
Th1 and Th2 populations. Moreover, 
Th17 cells are characterized by the pro­
duction of inflammatory cytokines such 
as IL­17A, IL­17F, IL­22, and IL­26. Th17 
cells have been implicated in several 
human autoimmune diseases, including 
multiple sclerosis, rheumatoid arthritis, 
inflammatory bowel disease, and psoria­
sis, as well as in the clearance of extracel­
lular pathogens (e.g., Candida albicans, 
Borrelia burgdoferi, Mycobacterium 
tuberculosis, and Streptococcus pneu-
moniae) (Tesmer et al., 2008).
The role of Th17 cells in allergy is 
still largely unresolved. Increased lev­
els of IL­17A have been reported in the 
peripheral blood, sputum, and airways of 
asthmatic patients and have been corre­
lated with the degree of bronchial hyper­
reactivity (Tesmer et al., 2008). IL­17A, 
|IL­17 and Th17 cells may have roles in AD.
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together with IL­22, could be respon­
sible for the acute inflammatory tissue 
remodeling promoting neutrophilic infil­
tration in the asthmatic airways through 
fibroblasts and epithelial cells, release 
of chemoattractants such as IL­8, and 
bronchoconstriction due to stimulation 
of airway smooth muscle cells (Galli et 
al., 2008; Molet et al., 2001). IL­17A 
is also able to induce IL­19 expres­
sion in airway epithelia synergistically 
with IL­4 and IL­13, enhancing a pos­
sible Th2 response (Huang et al., 2008). 
Epicutaneous immunization in mice 
with ovalbumin can cause allergic skin 
inflammation resembling AD, cutaneous 
expression of IL­17A and IL­17F mRNA, 
and, subsequently, airway inflammation 
(He et al., 2007). Another member of the 
IL­17 family, IL­17E, also denoted IL­25, 
has been implicated in Th2­mediated 
inflammatory responses, and IL­25 and 
IL­25R transcripts have been found to be 
elevated in AD lesions and in asthmatic 
lungs (Wang et al., 2007).
In this issue, Koga et al. (2008) dem­
onstrate the presence of Th17 cells and 
IL­17 in AD patients, suggesting partici­
pation by this newly recognized Th lin­
eage in the development of the disease. 
Phenotypic analysis of peripheral blood 
mononuclear cells derived from AD 
patients demonstrated a marked increase 
in the IL­17+CD4+ T­cell population com­
pared with healthy controls. The high­
est percentage of IL­17–producing cells 
was found in severe AD, suggesting a 
direct correlation between the presence 
of Th17 cells and severity of the disease. 
The mean percentage of IL­17–producing 
cells in psoriasis was slightly higher than 
that in severe AD, but the difference was 
not statistically significant. Increased lev­
els of IL­17 were also reported in cutane­
ous lesions of AD patients; localization 
of IL­17–producing cells was greater 
in the upper papillary dermis, but they 
were also found in the epidermis. Of 
note, IL­17 expression was much more 
evident in acute than in chronic lesions, 
confirming findings previously reported 
by Toda et al. (2003). Koga et al. (2008) 
also investigated the effect of IL­17 and 
IL­22 on normal human keratinocytes in 
vitro, demonstrating a synergistic effect 
of the two cytokines in the induction 
of GM­CSF, IL­8, CXCL10, and tumor 
necrosis factor­α. In addition, IL­17 was 
also able to modulate vascular endothe­
lial growth factor (VEGF) production.
How can we integrate the findings of 
Koga et al. (2008) into our current view 
of the pathogenesis of AD (see Figure 1)? 
The model of sequential activation of 
Th cells during the develop ment of AD 
suggests the presence of an initial acute 
phase dominated by professional 
antigen­presenting cells encountering 
and processing antigens (e.g., aeroaller­
gen, Staphylococcus aureus) and pre­
senting peptides to naive T cells, which 
in turn differentiate into Th2 cells, 
induce a B­cell­class switch to IgE, 
and migrate to the skin. IL­4 and IL­5 
released by Th2 cells recruit eosinophils 
to inflamed skin sites, which in turn 
produce IL­1β, IL­6, and IL­17E, the 
last being able to expand the numbers 
of Th2 cells and enhance Th2 cytokine 
production (Wang et al., 2007). IL­1β 
and IL­6, together with TGF­β, which 
has been found to be increased in cuta­
neous lesions of AD (Toda et al., 2003), 
could drive Th17 polarization. Cheung 
et al. (2008) demonstrated that IL­17A 
and IL­17F can promote eosinophil 
production of CXCL1, IL­8, and CCL4, 
as well as IL­1β and IL­6, indicating 
that there is possible cross­talk between 
Th17 cells and eosinophils in AD. 
Finally, eosinophils could contribute to 
the shift toward the late phase of AD by 
producing IL­12, which results in the 
Th2­to­Th1 switch.
A possible role for IL­17 in cutaneous 
remodeling in AD may be mediated by 
its ability to stimulate epithelial cells and 
fibroblasts to secrete proinflammatory 
Figure 1. model of sequential t helper cell involvement in aD. After the first contact with an antigen 
(e.g., aeroallergen or Staphylococcus aureus) during the elicitation phase, cutaneous professional 
antigen presenting cells migrate to regional lymph nodes, where they present processed peptides to 
naive T cells. In the presence of IL­4, naive T lymphocytes differentiate toward a Th2 phenotype and 
induce class switching of B lymphocytes to IgE production. Circulating IgE binds to high­affinity IgE 
receptors on tissue resident mast cells. A second exposure to the antigen causes cell reactivation, mast 
cell degranulation, and release of inflammatory molecules such as histamine, IL­8, and IL­13. This 
cytokine milieu causes an influx of Th2 lymphocytes and eosinophils into the skin, resulting in the 
production of Th2 cytokines (e.g., IL­4, IL­5, and IL­13), which in turn stimulate eosinophils to release 
IL­25, enhancing the Th2 environment. During the acute phase, eosinophils (producing IL­6, IL­1β, and 
transforming growth factor­β (TGF-β)) may support Th17 differentiation. Th17 cells may be recruited to 
the skin, where they interact with Th2 cells (potentially causing IL­19 release), keratinocytes (epidermal 
hyperplasia and release of antimicrobial peptides), and fibroblasts (tissue remodeling and fibrosis). IL­12 
secreted by eosinophils, dermal dendritic cells (DDCs), and inflammatory epidermal dendritic cells 
(IDEC) drives the shift toward the chronic phase of AD, which is predominantly characterized by a Th1 
phenotype. KC, keratinocyte; LC, Langerhans cell; MHC, major histocompatibility complex.
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cytokines such as IL­8, IL­6, and IL­11 
(Molet et al., 2001). These IL­17 activi­
ties could promote tissue fibrosis, chro­
nicity of the inflammatory process, and 
the evolution of chronic inflammatory 
cutaneous lesions. However, Koga et 
al. (2008) demonstrated lower levels of 
IL­17 during the chronic phase of AD, 
suggesting a possible Th17­to­Th1 shift 
in later phases of the disease. Their find­
ings suggest a link between innate and 
acquired immunity in allergy, highlight­
ing the relevance of balanced and recip­
rocal interaction among Th1, Th2, and 
Th17 cells in inflammation. Further stud­
ies are needed to clarify the role of Th17 
cells in the pathogenesis of AD, especial­
ly identification of the stage of the dis­
ease in which Th17 might play a role.
It will also be interesting to deter­
mine why, despite the presence of 
Th17 cells, there are no prominent 
neutrophilic infiltrates and no efficient 
protection against extracellular patho­
gens such as Staphylococcus aureus in 
AD. Th17 cells have been proposed to 
lead to neutrophil infiltration as a result 
of the production of IL­22 and IL­17A 
and the induction of IL­8 and anti­
microbial peptides in epithelial cells. 
This cascade may have pathological 
relevance both in asthma and in psori­
asis. Psoriasis and late­phase AD share 
many pathologic features, such as epi­
thelial hyperplasia, abnormal differen­
tiation of keratinocytes, and prominent 
T­lymphocyte and dendritic cell infil­
tration. Nevertheless, they have always 
been considered contrasting poles of 
immunopathologies because of the 
dichotomy of Th cells (Th2 versus Th1) 
and the presence of different subsets of 
leukocytes (eosinophils versus neutro­
phils) and dendritic cells. The presence 
of Th17 cells, in addition to Th1 cells, 
in AD provides a basis for a common 
effector pathway in AD and psoriasis, 
and this could partially explain some 
of their clinicopathologic similarities. 
Ultimately, this suggests that these 
inflammatory skin disorders might have 
common therapeutic targets.
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notch and Melanocytes: Diverse 
Outcomes from a single signal
Masatake Osawa1 and David E. Fisher1,2,3
notch signaling is an evolutionally conserved pathway that serves as a critical 
regulator of cell fate. From a series of studies, including a report in this issue, 
researchers have begun to elucidate the critical functions of notch signaling in 
the regulation of melanocyte lineage development. With evidence of a recent-
ly identified role for notch signaling in melanomagenesis, characterization of 
downstream molecular events may offer potential avenues for the development 
of novel therapeutic strategies.
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Single signal, diverse outcomes: a critical 
question in developmental biology
Tissue organogenesis is governed by 
a remarkably small set of evolution­
ally conserved signaling pathways. 
These signals, which may be termed 
a “developmental toolkit,” include 
the BMP, FGF, Notch, Hedgehog, and 
Wnt signaling pathways (Canestro et 
al., 2007). During development, these 
toolkit signaling pathways are utilized 
in a diverse range of discrete cell lin­
eages in a spaciotemporally regulat­
ed manner to build a wide variety of 
